

Stanford

Xinrong Zhang

Postdoctoral Scholar, Gastroenterology

Bio

INSTITUTE AFFILIATIONS

- Member, Maternal & Child Health Research Institute (MCHRI)

STANFORD ADVISORS

- Mindie Nguyen, Postdoctoral Faculty Sponsor
- Mindie Nguyen, Postdoctoral Research Mentor

Publications

PUBLICATIONS

- **MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic-associated fatty liver disease.** *Alimentary pharmacology & therapeutics*
Cheung, J. T., Zhang, X., Wong, G. L., Yip, T. C., Lin, H., Li, G., Leung, H. H., Lai, J. C., Mahadeva, S., Nik Mustapha, N. R., Wang, X., Liu, W., Wong, et al
2023
- **Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial** *GUT*
Zhang, X., Yip, T., Wong, G., Leow, W., Liang, L., Lim, L., Li, G., Ibrahim, L., Lin, H., Lai, J., Chim, A., Chan, H., Kong, et al
2023
- **Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: A landmark analysis** *HEPATOLOGY*
Zhang, X., Yip, T., Tse, Y., Hui, V., Li, G., Lin, H., Liang, L., Lai, J., Chan, H., Chan, S., Kong, A., Wong, G., Wong, et al
2023: 1816-1827
- **Editorial: improvement of cardiovascular risk factor control in patients with type 2 diabetes and nonalcoholic fatty liver disease-time for action! Authors' reply.** *Alimentary pharmacology & therapeutics*
Zhang, X., Wong, G. L., Wong, V. W., Yip, T. C.
2023; 57 (10): 1172-1173
- **Trends in risk factor control and treatment among patients with non-alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory-wide study** *ALIMENTARY PHARMACOLOGY & THERAPEUTICS*
Zhang, X., Yip, T., Tse, Y., Hui, V., Li, G., Lin, H., Liang, L., Lai, J., Lai, M., Cheung, J. K., Chan, H., Chan, S., Kong, et al
2023; 57 (10): 1103-1116
- **Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease.** *Hepatology (Baltimore, Md.)*
Zhang, X., Wong, G. L., Yip, T. C., Cheung, J. T., Tse, Y. K., Hui, V. W., Lin, H., Lai, J. C., Chan, H. L., Kong, A. P., Wong, V. W.
2022; 76 (5): 1409-1422
- **Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease.** *Hepatology (Baltimore, Md.)*
Zhang, X., Wong, G. L., Yip, T. C., Tse, Y. K., Liang, L. Y., Hui, V. W., Lin, H., Li, G. L., Lai, J. C., Chan, H. L., Wong, V. W.
2022; 76 (2): 469-482
- **Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease.** *Journal of clinical and translational hepatology*
Lin, H., Zhang, X., Li, G., Wong, G. L., Wong, V. W.
2021; 9 (6): 972-982

- **Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory-Wide Cohort Study.** *Hepatology communications*
Zhang, X., Wong, V. W., Yip, T. C., Tse, Y. K., Liang, L. Y., Hui, V. W., Li, G. L., Chan, H. L., Wong, G. L.
2021; 5 (7): 1212-1223
- **Unhealthy lifestyle habits and physical inactivity among Asian patients with non-alcoholic fatty liver disease.** *Liver international : official journal of the International Association for the Study of the Liver*
Zhang, X., Goh, G. B., Chan, W. K., Wong, G. L., Fan, J. G., Seto, W. K., Huang, Y. H., Lin, H. C., Lee, I. C., Lee, H. W., Kim, S. U., Chow, W. C., Wong, et al
2020; 40 (11): 2719-2731
- **Application of transient elastography in nonalcoholic fatty liver disease.** *Clinical and molecular hepatology*
Zhang, X., Wong, G. L., Wong, V. W.
2020; 26 (2): 128-141
- **A liver stiffness-based etiology-independent machine learning algorithm to predict hepatocellular carcinoma.** *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*
Lin, H., Li, G., Delamarre, A., Ahn, S. H., Zhang, X., Kim, B. K., Liang, L. Y., Lee, H. W., Lai-Hung Wong, G., Yuen, P., Lik-Yuen Chan, H., Chan, S. L., Wai-Sun Wong, et al
2023
- **COMPARISON OF CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE WHO DID OR DIDN'T RECEIVE LIVER BIOPSY**
Zhang, X., Kam, L., Barnett, S. D., Henry, L., Cheung, R., Nguyen, M. H.
LIPPINCOTT WILLIAMS & WILKINS.2023: S931
- **Diagnostic and prognostic performance of the SAFE score in non-alcoholic fatty liver disease.** *Liver international : official journal of the International Association for the Study of the Liver*
Li, G., Lin, H., Sripongpan, P., Liang, L. Y., Zhang, X., Wong, V. W., Wong, G. L., Kim, W. R., Yip, T. C.
2023
- **Dynamic Glucose-Enhanced Imaging of the Liver Using Breath-Hold Black Blood Quantitative T1# MRI at 3.0 T.** *Journal of magnetic resonance imaging : JMRI*
Qian, Y., Wong, V. W., Wang, Y. X., Hou, J., Jiang, B., Zhang, X., Wong, G. L., Chan, Q., Yu, S. C., Chu, W. C., Chen, W.
2023
- **Diagnostic and prognostic performance of the SAFE score in nonalcoholic fatty liver disease**
Li, G., Lin, H., Sripongpan, P., Liang, Y., Zhang, X., Wong, V., Wong, G., Kim, W., Yip, T.
ELSEVIER.2023: S663-S664
- **Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease** *HEPATOLOGY*
Lin, H., Yip, T., Zhang, X., Li, G., Tse, Y., Hui, V., Liang, L., Lai, J., Chan, S., Chan, H., Wong, G., Wong, V.
2023; 77 (2): 573-584
- **Trimethylamine-N-Oxide Aggravates Kidney Injury via Activation of p38/MAPK Signaling and Upregulation of HuR.** *Kidney & blood pressure research*
Lai, Y., Tang, H., Zhang, X., Zhou, Z., Zhou, M., Hu, Z., Zhu, F., Zhang, L., Nie, J.
2022; 47 (1): 61-71
- **Universal HBV vaccination dramatically reduces the prevalence of HBV infection and incidence of hepatocellular carcinoma.** *Alimentary pharmacology & therapeutics*
Wong, G. L., Hui, V. W., Yip, T. C., Liang, L. Y., Zhang, X., Tse, Y. K., Lai, J. C., Chan, H. L., Wong, V. W.
2022; 56 (5): 869-877
- **Reply.** *Hepatology (Baltimore, Md.)*
Zhang, X., Wong, G. L., Yip, T. C., Wong, V. W.
2022; 76 (2): E34-E35
- **Gut microbial metabolite TMAO increases peritoneal inflammation and peritonitis risk in peritoneal dialysis patients.** *Translational research : the journal of laboratory and clinical medicine*
Zhang, L., Xie, F., Tang, H., Zhang, X., Hu, J., Zhong, X., Gong, N., Lai, Y., Zhou, M., Tian, J., Zhou, Z., Xie, L., Hu, et al
2022; 240: 50-63

- **U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases.** *Clinical and molecular hepatology*
Lin, H., Wong, G. L., Zhang, X., Yip, T. C., Liu, K., Tse, Y. K., Hui, V. W., Lai, J. C., Chan, H. L., Wong, V. W.
2022; 28 (1): 77-90
- **Association of metformin use on metabolic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis and renal impairment.** *Health science reports*
Yip, T. C., Chan, R. N., Wong, V. W., Tse, Y. K., Liang, L. Y., Hui, V. W., Zhang, X., Li, G. L., Chan, H. L., Wong, G. L.
2021; 4 (3): e352
- **Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss.** *Alimentary pharmacology & therapeutics*
Yip, T. C., Wong, V. W., Tse, Y. K., Liang, L. Y., Hui, V. W., Zhang, X., Li, G. L., Lui, G. C., Chan, H. L., Wong, G. L.
2021; 53 (2): 321-331